Dalbavantsin - novaya vozmozhnost' v lechenii infektsiy kozhi i myagkikh tkaney, vyzvannykh rezistentnym Staphylococcus aureus


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Starting from the 2000s, infections caused by MRSA (Methicillin-Resistant Staphylococcus aureus) ceased to be exclusively nosocomial problem due to wide occurrence. The development of new antibiotics active against MRSA is a very urgent task. In the USA in May 2014, for the treatment of infections of the skin and soft tissue caused by Gram-positive organisms, including MRSA, new antibiotic -dalbavancin, a semisynthetic lypoglycopeptide, was released. Despite the favorable tolerability demonstrated in clinical studies, experts have expressed concerns about the safety of this drug, and warn against the off-label use of drug, for example in bacteremia or pneumonia. Apparently, the benefit/risk ratio of dalbavancin should be determined by its application in general medical practice.

全文:

受限制的访问

参考

  1. Pope S.D., Roecker A.M. Dalbavancin: a novel lipoglycopeptide antibacterial. Pharmacotherapy. 2006;26;908-18.
  2. Rasigade J.P., Dumitrescu O., Lina G. New epidemiology of Staphylococcus aureus infections. Clin. Microbiol. infect. 2014 Jun 14. [Epub ahead of print].
  3. Boucher H. W. Challenges in anti-infective development in the era of bad bugs, no drugs: A regulatory perspective using the example of bloodstream infection as an indication. Clin. infectious Dis. 2010;50:S4-9.
  4. Appelbaum P.C. MRSA--the tip of the iceberg. Clin. Microbiol, infect. 2006;12(Suppl2):3-10.
  5. Szekely E., Lorinczi L., Bilca D., et al. incidence, antibiotic resistance and clonal relations of MRSA strains isolated from a Romanian university hospital. Acta Microbiol immunol Hung 2008;55:1-13.
  6. Cowcroft N., Duckworth G., Griffiths C., et al. Deaths involving MRSA: England and Wales, 1993-2006. Health Stat Q. 2008;37:57-6.
  7. Klevens R.M., Edwards J.R., Tenover F.C., et al. Changes in the epidemiology of methicillinresistant Staphylococcus aureus in intensive care units in U.S. hospitals, 1992-2003. Clin. infect. Dis. 2006;42:389-91.
  8. Köck R., Becker K., Cookson B., et al. Methicillinresistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill. 2010;15(41):19688.
  9. National nosocomial infections surveillance (NNiS) system report, data summary from January 1992 through June 2004 issued October 2004. Am. J. infect. Control. 2004;32:470-85. infect Control Hosp Epidemiol. 2008;29(11):996-1011.
  10. Hidron A.i., Edwards J.R., Patel J., et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007.
  11. Klevens R.M., Morrison M.A., Nadle J. invasive methicillin -resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298(15): 1763-71.
  12. Boucher H.W., Corey G.R. Epidemiology of methicillin -resistant Staphylococcus aureus. Clin. infect. Dis. 2008;46(Suppl 5):S344-49.
  13. Ohlsen К. Novel Antibiotics for the Treatment of Staphylococcus aureus. Expert Rev. Clin. Pharmacol. 2009;2(6):661-72.
  14. Stefani S., Chung D.R., Lindsay J.A., Friedrich A.W., Kearns A.M., et al. Methicillin-resistant Staphylococcus aureus (MRSA): Global epidemiology and harmonisation of typing methods. Int. J. Antimicrob Agents. 2012;39:273-82.
  15. Zetola N, Francis J.S., Nuermberger E.L., Bishai W.R. Community-acquired methicillin-resistant Staphylococcus aureus: An emerging threat. Lancet Infect. Dis 2005;5:275-86.
  16. Roberts J.C., Krueger R.L., Peak K.K., et al. Community-associated methicillin-resistant Staphylococcus aureus epidemic clone USA300 in isolates from Florida and Washington. J.Clin. Microbiol. 2006;44(1 ):225-26.
  17. Miller L.G., Perdreau-Remington F., Rieg G., et al. Necrotizing fasciitis caused by community-associated methicillin-resistant: Staphylococcus aureus in Los Angeles. N. Engl. J. Med. 2005;352(14):1445-53.
  18. Dominguez T.J. It's not a spider bite, it's community-acquired methicillin-resistant Staphylococcus aureus. J. Am. Board.Family Pract. 2004;17(3):220-26.
  19. Heymann W.R. Community-acquired methicillin-resistant Staphylococcus aureus infection. J.the Am. Acad. Dermatol. 2005;53(2):318-19.
  20. Weber J.T. Community-associated methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 2005;41(supplement 4) :S269-72.
  21. Pantosti A. Methicillin-resistant Staphylococcus aureus associated with animals and its relevance to human health. Front Microbiol. 2012;3:127.
  22. Graveland H., Duim B., van Duijkeren E., Heederik D., Wagenaar J.A. Livestock-associated methicillin-resistant Staphylococcus aureus in animals and humans. Int. J. Med. Microbiol. 2011;301:630-34.
  23. Himsworth C.G., Parsons K.L., Jardine C., Patrick D.M. Rats, cities, people, and pathogens: A systematic review and narrative synthesis of literature regarding the epidemiology of rat-associated zoonoses in urban centers. Vector Borne Zoonotic Dis. 2013;13:349-59.
  24. Himsworth C.G., Miller R.R., Montoya V., et al. Carriage of methicillin-resistant Staphylococcus aureus by wild urban Norway rats (Rattus norvegicus). PLoS One. 2014;9(2):e87983.
  25. European Food Safety Authority: Analysis of the baseline survey on the prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in holding with breeding pigs in the EU, 2008, Part A: MRSA prevalence estimates. EFSA Journal. 2009;7:1376.
  26. Spoor L.E., McAdam P.R., Weinert L.A., et al. Livestock origin for a human pandemic clone of community-associated methicillin-resistant Staphylococcus aureus. MBio. 2013;4(4): pii: e00356-13.
  27. Gordon R.J., Lowy F.D. Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clin. Infect. Dis. 2008;46(Suppl. 5):S350-59.
  28. Cosgrove S.E., Sakoulas G., Perencevich E.N., et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. Infect. Dis. 2003;36:53-59.
  29. Shurland S., Zhan M., Bradham D.D., Roghmann M.C. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect. Control Hosp. Epidemiol. 2007;28:273-79.
  30. Cosgrove S.E., Qi Y., Kaye K.S., Harbarth S., et al. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect. Control Hosp. Epidemiol. 2005;26:166-74.
  31. Zahar J.R., Clech C., Tafflet M., et al. Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia? Clin. Infect. Dis. 2005;41:1224-31.
  32. Engemann J.J., Carmeli Y., Cosgrove S.E., et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin. Infect. Dis. 2003;36:592-98.
  33. Wilcox MH. MRSA new treatments on the horizon: current status. Injury. 2011;42(Suppl 5):S42-4.
  34. Projan S.J. Why is big Pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. 2003;6:427-30.
  35. Witte W., Cuny C., Klare I., Nubel U., Strommenger B., Werner G. Emergence and spread of antibiotic-resistant Gram-positive bacterial pathogens. Int. J. Med. Microbiol. 2008;298:365-77.
  36. Gardete S., Tomasz A. Mechanisms of vancomycin resistance in Staphylococcus aureus. J. Clin. Invest. 2014;124(7):2836-40.
  37. Дехнич А.В. Выявление резистентности к метициллину и другим лактамным антибиотикам методом скрининга: Метод. рекомендации для микробиологов. http://www.antibiotic.ru/rus/all/ metod/meticres.
  38. O'Brien D.J., Gould I.M. Does vancomycin have a future in the treatment of skin infections? Curr. Opin. Infect. Dis. 2014;27(2):146-54.
  39. Dalbavancin: New Option for Skin and Skin Structure Infections. Medscape. May 23, 2014.
  40. Pfizer Inc. Pfizer receives approvable letter from FDA for dalbavancin. December 21, 2007. http:// mediaroom.pfizer.com/portal/site/pfizer/index. jsp?ndmViewId=news_view&newsId=20071221005 672&newsLang=en.
  41. Pfizer Inc. Pfizer will withdraw global marketing applications for dalbavancin to conduct a new trial. September 6, 2008.www.pfizer.be/Media/Press+bulletins/Rese arch+and+development+and+business+developme nt/Withdraw+dalbavancin+market+applications.htm.
  42. Zhanel G.G., Calic D., Schweizer F., et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs. 2010;70:859-86.
  43. Bailey J., Summers K.M. Dalbavancin: a new lipoglycopeptide antibiotic. Am. J. Health Syst. Pharm. 2008;65:599-610.
  44. Burke S.L., Rose W.E. New pharmacological treatments for methicillin-resistant Staphylococcus aureus infections. Expert Opin Pharmacother. 2014;15(4): 483-91.
  45. Buckwalter M., Dowell J.A. Population pharmacokinetic analysis of dalbavancin a novel lipoglycopeptide. J. Clin Pharmacol. 2005;45:1279-87.
  46. Raad, Darouiche R., Vazquez J., et al. Efficacy and safety of weekly dalbavancin therapy for catheter related bloodstream infection caused by gram-positive pathogens. Clin. Infect. Dis. 2005;40:374-80.
  47. Boucher H.W., Wilcox M., Talbot G.H., et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N. Engl. J. Med. 2014;370(23):2169-79.
  48. US Food and Drug Administration. FDA Briefing Document. Anti-infective Drugs Advisory Committee Meeting. March 31, 2014. http:// www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM390792.pdf Accessed May 16, 2014.
  49. Jauregui L.E., Babazadeh S., Seltzer E., et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis. 2005;41(10):1407-15.
  50. Chambers H.F. Pharmacology and the Treatment of Complicated Skin and Skin-Structure Infections. N. Engl. J. Med. 2014;370:2238-39. Dalbavancin, Oritavancin Safe, Effective for Skin Infection. Medscape. Jun 06, 2014.
  51. US Food and Drug Administration. FDA Briefing Document. Anti-infective Drugs Advisory Committee Meeting. March 31, 2014. http:// www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM390792.pdf Accessed May 16, 2014
  52. Dalbavancin, Oritavancin Safe, Effective for Skin Infection. Medscape. Jun 06, 2014.
  53. New Antibiotic Tedizolid (Sivextro) Approved by FDA. Medscape. Jun 20, 2014.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2014
##common.cookie##